Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAP trial: therapeutic drug monitoring for antimicrobial agents in adults living with HIV
PACTR202409710100607Not yet recruiting
- Sponsor
- Infectious Diseases Institute
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rifampicin and isoniazid in Tuberculosis (TB), sponsored by Infectious Diseases Institute. Primary endpoints: Trough concentration and Maximum concentration. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
rifampicinisoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202409710100607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202409710100607.